News >

CRISPR Technology Seeking to Inactivate Mutated Genes in Lung Cancer

Gina Columbus @ginacolumbusonc
Published: Tuesday, Aug 15, 2017

Monte Winslow, PhD

Monte Winslow, PhD
Academic researchers are hoping that their efforts on the gene-editing technology of CRISPR (clustered regularly interspaced short palindromic repeats) will lead to the ability of turning off mutated genes in patients with a variety of malignancies, including lung cancer.

on Advanced Non–Small Cell Lung Cancer, he shared the work on CRISPR being developed in his lab, and how this technology might help advance treatment for the non-driver NSCLC population.

OncLive: What did you highlight regarding CRISPR technology in your presentation?

Winslow: The main thing that we are interested in doing is developing model systems where we can generate many different types of tumors in mouse models. These are very important cancer genes. Can we create mouse models of human cancer? We have a diversity of different genes mutated. We are looking at the diversity of different genotypes of tumors in individual mice so we can first learn about the biology of how these genes being mutated impacts cancer development, or cancer progression, in the lung.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication